Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

Zhengye Biotechnology Holding Limited (ZYBT) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

Zhengye Biotechnology Holding Limited (ZYBT), most recent 12 months reported: revenue $16.64M, net loss $9.98M, free cash flow $1.77M. Latest balance sheet on file: liquid cash $7.42M, total debt $10.68M, net cash -$3.25M. From SEC filings. Others in Pharmaceutical Preparations: Celularity Inc. · CytomX Therapeutics, Inc. · uniQure N.V. · EVOFEM BIOSCIENCES, INC. · EMMAUS LIFE SCIENCES, INC. · Keros Therapeutics, Inc. · Pyxis Oncology, Inc. · PALATIN TECHNOLOGIES, INC.

Stock screener

Watchlist